Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects

NCT02235961 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and side effects of a single dose of the experimental drug NNC9204-0530, both alone and when combined with liraglutide, in healthy men who are overweight or obese.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 163 people

Who can join Ages 18–55 · male only Healthy volunteers accepted.

Timeline Started 2014-09 · est. completion 2016-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02235961 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America (USA). The aim of the trial is to investigate safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) for single doses of NNC9204-0530 alone and in combination with liraglutide in overweight to obese but otherwise healthy male subjects.

Treatments tested

NNC9204-0530 Drug

Administered as single subcutaneous (s.c., under the skin) injections.
liraglutide Drug

Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
placebo Drug

Administered as single subcutaneous (s.c., under the skin) injections.

Main thing measured	Number of treatment emergent adverse events recorded
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02235961 ↗